Literature DB >> 19767760

Uptake of resveratrol and role of resveratrol-targeting protein, quinone reductase 2, in normally cultured human prostate cells.

Tze-Chen Hsieh1.   

Abstract

Resveratrol is a dietary polyphenol espoused to have chemopreventive activity against a variety of human cancer types. We first reported that resveratrol significantly decreases the proliferation of both androgen-dependent and hormone-refractory prostate cancer cells. However, the effects of resveratrol in normal prostate epithelial and stromal cells, particularly with regard to its uptake, subcellular distribution and intracellular targets, have not been investigated. To advance the knowledge on accessibility and cellular disposition of resveratrol in prostate cells, [(3)H] resveratrol, fractionation of cell extracts into subcellular compartments, Western blot analysis, resveratrol affinity column chromatography and flow cytometry were used to study the uptake and intracellular distribution of resveratrol in normally cultured prostate stromal (PrSCs) and epithelial cells (PrECs). Pretreatment of both PrSCs and PrECs for 2 days with resveratrol modulated its uptake and selectively increased its distribution to the membrane and organelle compartments. Resveratrol affinity column chromatography studies showed differential expression of a previously identified resveratrol-targeting protein, quinone reductase 2 (QR2), in PrSCs and PrECs. Flow cytometric analysis comparing resveratrol-treated and untreated PrSCs showed a large decrease in G(1)-phase and a concomitant increase in S and G(2)/M-phases of the cell cycle. These results suggest that resveratrol suppresses PrSC proliferation by affecting cell cycle phase distribution, which may involve the participation by QR2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19767760      PMCID: PMC3735322          DOI: 10.1038/aja.2009.56

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  39 in total

Review 1.  Resveratrol and cancer: a review.

Authors:  J F Savouret; M Quesne
Journal:  Biomed Pharmacother       Date:  2002-03       Impact factor: 6.529

Review 2.  A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol.

Authors:  J Gusman; H Malonne; G Atassi
Journal:  Carcinogenesis       Date:  2001-08       Impact factor: 4.944

Review 3.  Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine (Review).

Authors:  J M Wu; Z R Wang; T C Hsieh; J L Bruder; J G Zou; Y Z Huang
Journal:  Int J Mol Med       Date:  2001-07       Impact factor: 4.101

4.  Identification of the melatonin-binding site MT3 as the quinone reductase 2.

Authors:  O Nosjean; M Ferro; F Coge; P Beauverger; J M Henlin; F Lefoulon; J L Fauchere; P Delagrange; E Canet; J A Boutin
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

5.  Benefits of resveratrol in women's health.

Authors:  D Bagchi; D K Das; A Tosaki; M Bagchi; S C Kothari
Journal:  Drugs Exp Clin Res       Date:  2001

6.  Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis.

Authors:  Michelle Mouria; Anna S Gukovskaya; Yoon Jung; Peter Buechler; Oscar J Hines; Howard A Reber; Stephen J Pandol
Journal:  Int J Cancer       Date:  2002-04-10       Impact factor: 7.396

7.  Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol.

Authors:  S U Singh; R F Casper; P C Fritz; B Sukhu; B Ganss; B Girard; J F Savouret; H C Tenenbaum
Journal:  J Endocrinol       Date:  2000-10       Impact factor: 4.286

8.  Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis.

Authors:  Y Schneider; B Duranton; F Gossé; R Schleiffer; N Seiler; F Raul
Journal:  Nutr Cancer       Date:  2001       Impact factor: 2.900

9.  Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line.

Authors:  Hung-Yun Lin; Ai Shih; Faith B Davis; Heng-Yuan Tang; Leon J Martino; James A Bennett; Paul J Davis
Journal:  J Urol       Date:  2002-08       Impact factor: 7.450

Review 10.  Cancer chemopreventive activity of resveratrol.

Authors:  Krishna P L Bhat; John M Pezzuto
Journal:  Ann N Y Acad Sci       Date:  2002-05       Impact factor: 5.691

View more
  6 in total

Review 1.  Resveratrol: Biological and pharmaceutical properties as anticancer molecule.

Authors:  Tze-chen Hsieh; Joseph M Wu
Journal:  Biofactors       Date:  2010 Sep-Oct       Impact factor: 6.113

2.  Control of stability of cyclin D1 by quinone reductase 2 in CWR22Rv1 prostate cancer cells.

Authors:  Tze-chen Hsieh; Ching-Jen Yang; Chia-Yi Lin; Yong-Syu Lee; Joseph M Wu
Journal:  Carcinogenesis       Date:  2012-01-19       Impact factor: 4.944

3.  Design, synthesis, and biological evaluation of potent quinoline and pyrroloquinoline ammosamide analogues as inhibitors of quinone reductase 2.

Authors:  P V Narasimha Reddy; Katherine C Jensen; Andrew D Mesecar; Phillip E Fanwick; Mark Cushman
Journal:  J Med Chem       Date:  2011-12-29       Impact factor: 7.446

4.  Modulating Oxidative Stress Relieves Stress-Induced Behavioral and Cognitive Impairments in Rats.

Authors:  Naimesh Solanki; Ankita Salvi; Gaurav Patki; Samina Salim
Journal:  Int J Neuropsychopharmacol       Date:  2017-07-01       Impact factor: 5.176

5.  Biochemical and cellular evidence demonstrating AKT-1 as a binding partner for resveratrol targeting protein NQO2.

Authors:  Tze-chen Hsieh; Chia-Yi Lin; Dylan John Bennett; Erxi Wu; Joseph M Wu
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

6.  Resveratrol Suppresses Prostate Cancer Epithelial Cell Scatter/Invasion by Targeting Inhibition of Hepatocyte Growth Factor (HGF) Secretion by Prostate Stromal Cells and Upregulation of E-cadherin by Prostate Cancer Epithelial Cells.

Authors:  Tze-Chen Hsieh; Joseph M Wu
Journal:  Int J Mol Sci       Date:  2020-03-04       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.